Skip to content

Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease

Ancillary Study of Oxidative Stress and Anti-Inflammatory Lipids in Airway Disease in the MIA (ACRN) and LEUKO (CCRN) Trials

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00595114
Enrollment
43
Registered
2008-01-16
Start date
2007-12-31
Completion date
2009-08-31
Last updated
2016-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Pulmonary Disease, Chronic Obstructive

Keywords

COPD, Airway, Inflammation, Infection, Lipid Mediators, Oxidative Stress

Brief summary

Chronic obstructive pulmonary disease (COPD) and asthma are common respiratory diseases in which people experience long-term inflammation of the lungs. Exacerbations, or prolonged worsening of symptoms, of asthma and COPD are often life-threatening and can lead to frequent need for hospitalization. Even with the proper use of bronchodilators, corticosteroids, and other currently available medications, clinical responses among people with COPD and asthma are variable. There remains a significant unmet clinical need for new therapeutic approaches and insights, including the identification of biomarkers to accurately assess the presence of airway infection and intensity of airway inflammation. This study will investigate potential natural biological causes and new biomarkers for increased susceptibility to persistent airway infection in asthma and COPD.

Detailed description

COPD and asthma are chronic lung diseases that result in impaired air flow in the lungs, often causing coughing, wheezing, and shortness of breath. In uncontrolled COPD and asthma, people may experience a rapid worsening of symptoms, which may include fever, difficulty breathing, and chest pain. These exacerbations are the most serious expression of asthma and COPD and are usually caused by lung infections or air allergens. However, the biological basis for susceptibility to airway infection and inflammation is not well understood. Increased oxidative stress within the airways has been linked to several airway diseases. This increase in oxidative stress may reduce production of key fatty acid anti-inflammatory mediators. In turn, this may disrupt the airway's natural immune response mechanisms, making the airways more vulnerable to infection or inflammation during COPD and asthma exacerbations. This ancillary study will determine whether susceptibility to persistent airway infection in asthma and COPD stems from increased oxidative stress that impairs the natural formation of protective fatty acid mediators. This ancillary study will use data biological samples, including blood and sputum, from participants currently enrolled in the Macrolides in Asthma (MIA; NCT00318708) and the Antileukotriene Therapy for COPD Exacerbations (KIA; NCT01097694). Biological samples will undergo fatty acid mediator analysis and RNA isolation. There will be no study visits for this study.

Interventions

None listed

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* No change from the MIA and LEUKO trials

Exclusion criteria

* No change from the MIA and LEUKO trials

Design outcomes

Primary

MeasureTime frameDescription
8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in AsthmaMeasured at completion of sample analysis8-isoprostane levels in sputum

Countries

United States

Participant flow

Participants by arm

ArmCount
MIA 1
Participants from the MIA trial with mild asthma
24
KIA 1
Participants from the KIA trial with severe asthma
19
Total43

Baseline characteristics

CharacteristicMIA 1TotalKIA 1
Age, Continuous37 years
STANDARD_DEVIATION 10
38 years
STANDARD_DEVIATION 10
40 years
STANDARD_DEVIATION 11
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants8 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
19 Participants35 Participants16 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
15 Participants23 Participants8 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
9 Participants20 Participants11 Participants
Region of Enrollment
United States
24 participants43 participants19 participants
Sex: Female, Male
Female
17 Participants26 Participants9 Participants
Sex: Female, Male
Male
7 Participants17 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 240 / 19
serious
Total, serious adverse events
0 / 240 / 19

Outcome results

Primary

8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma

8-isoprostane levels in sputum

Time frame: Measured at completion of sample analysis

ArmMeasureValue (MEAN)Dispersion
MIA 18-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma292.4 pg/mlStandard Deviation 51
KIA 18-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma421.8 pg/mlStandard Deviation 195.4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026